RBD-Based COVID-19 Vaccines: Technologies and Immune Responses
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".
Deadline for manuscript submissions: 28 February 2027 | Viewed by 636
Special Issue Editor
Interests: vaccine development; conjugate vaccines; nanotechnology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The emergence of the COVID-19 pandemic in 2019 led to unprecedented efforts in vaccine development. Effective vaccines using various platforms have played a vital role in controlling the pandemic. Initially, most subunit vaccines targeted the spike protein of SARS-CoV-2. However, vaccines based on the spike protein's receptor-binding domain (RBD) have also proven themselves to be effective. The neutralizing antibodies target the RBD, which is smaller than the whole spike protein. This focus can enhance manufacturing and help minimize non-neutralizing antibody production. This Special Issue invites submissions of original research, reviews, clinical trial results, and opinions related to RBD and spike protein-based vaccines, demonstrating the application of different vaccine technologies to induce immune response.
Dr. Puthupparampil Scaria
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- RBD vaccine
- COVID-19
- vaccine
- SARS-CoV-2
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
